**South Carolina General Assembly**

126th Session, 2025-2026

**H. 4545**

**STATUS INFORMATION**

Concurrent Resolution

Sponsors: Rep. Magnuson

Document Path: LC-0145AHB-AHB25.docx

Introduced in the House on May 8, 2025

Currently residing in the House

Summary: Sine Die Addition

**HISTORY OF LEGISLATIVE ACTIONS**

Date Body Action Description with journal page number

5/8/2025 House Introduced

5/8/2025 House Committed to Committee on **Rules**

5/8/2025 House Roll call Yeas-89 Nays-20

View the latest  [legislative information](https://www.scstatehouse.gov/billsearch.php?billnumbers=4545&session=126&summary=B)  at the website

**VERSIONS OF THIS BILL**

[05/08/2025](https://www.scstatehouse.gov/sess126_2025-2026/prever/4545_20250508.docx)

A concurrent RESOLUTION

to provide that in addition to the matters which may be CONSIDERED by the general assembly after May 8, 2025, pursuant to the sine die resolution for the 2025 legislative session as passed by the general assembly, H. 4262 relating to restricting, regulating, or prohibiting mrna gene therapies also may be introduced, received, and considered by each body of the general assembly prior to sine die adjournment including, but not limited to, concurrence, nonconcurrence, and appointment of conferees; receipt, consideration, AND DISPOSITION OF CONFERENCE AND FREE CONFERENCE REPORTS; AND RECEIPT, CONSIDERATION, AND DISPOSITION OF ANY VETOES, IF APPLICABLE.

Be it resolved by the House of Representatives, the Senate concurring:

That in addition to matters which may be considered by the General Assembly after May 8, 2025, pursuant to the Sine Die Resolution for the 2025 Legislative Session as passed by the General Assembly, the following matters may be introduced, received, and considered by each body of the General Assembly prior to Sine Die Adjournment including, but not limited to, concurrence, nonconcurrence, and appointment of conferees; receipt, consideration, and disposition of conference and free conference reports; and receipt, consideration, and disposition of any vetoes, if applicable:

(1) H. 4262 relating to restricting, regulating, or prohibiting mRNA gene therapies.

‑‑‑‑XX‑‑‑